



(51) International Patent Classification:

B01D 69/08 (2006.01) **B01D 71/26** (2006.01)
B01D 53/22 (2006.01)

(21) International Application Number:

PCT/US2017/028525

(22) International Filing Date:

20 April 2017 (20.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16166434.7 21 April 2016 (21.04.2016) EP

(71) Applicants: **3M INNOVATIVE PROPERTIES COMPANY** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US). **DMF MEDICAL INCORPORATED** [CA/CA]; 1344 Summer Street, Suite 308, Halifax, Nova Scotia B3H 0A8 (CA).

(72) Inventors: **VOIGT, Ina**; Carl-Schurz-Strasse 1, D-41453 Neuss (DE). **ANSORGE, Wolfgang**; Carl-Schurz-Strasse 1, D-41453 Neuss (DE). **WILFART, Florentin**; 1344 Summer Street, Suite 308, Halifax, Nova Scotia B3H 0A8 (CA). **SCHMIDT, Michael**; 5960 McCulloch Court, Halifax, Nova Scotia B3N 3H8 (CA). **HAELSSIG, Jan**; 1254 Hollis Street, Apartment 210, Halifax, Nova Scotia B3J 1T6 (CA).

(74) Agent: **BAUM, Scott A.** et al.; 3M Center, Office of Intellectual Property Counsel Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,

SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HOLLOW FIBER MEMBRANE FOR USE IN AN ANESTHETIC CIRCUIT

(57) Abstract: Hydrophobic poly(4-methyl-1-pentene) hollow fiber membrane for retention of anesthetic agents with an inner and an outer surface and between inner and outer surface an essentially isotropic support layer with a sponge-like, open-pored, microporous structure free of macrovoids and adjacent to this support layer on the outer surface a dense separation layer with a thickness between 1.0 and 3.5 μm . The membrane has a porosity in the range of greater than 35% to less than 50% by volume and a permeance for CO_2 of 20-60 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$, a gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ of at least 5 and a selectivity $\text{CO}_2/\text{anesthetic agents}$ of at least 150. The process for producing this membrane is based on a thermally induced phase separation process in which process a homogeneous solution of a poly(4-methyl-1-pentene) in a solvent system containing components A and B is formed, wherein component A is a strong solvent and component B a weak non-solvent for the polymer component. After formation of a hollow fiber the hollow fiber is cooled in a liquid cooling medium to form a hollow fiber membrane. The concentration of the polymer component in the solution may be in the range from 42.5 to 45.8 wt.-% and the hollow fiber leaving the die runs through a gap between die and cooling medium with a gap length in the range of 5-30 mm.



HOLLOW FIBER MEMBRANE FOR USE IN AN ANESTHETIC CIRCUIT

Description:

5 The invention relates to a hydrophobic integrally asymmetrical hollow fiber membrane that is suited in particular for gas exchange, is composed primarily of a poly(4-methyl-1-pentene) and has an inner surface facing towards its lumen, an outer surface facing outwards, the membrane having between inner surface and outer surface a support layer with a sponge-like, open-pored, microporous structure
10 and adjacent to this support layer on the outer surface a separation layer with denser structure, wherein the support layer is free of macrovoids and the pores in the support layer are on average essentially isotropic.

The invention relates further to a process for manufacturing this membrane using a
15 thermally induced phase separation process, the membrane having a sponge-like, open-pored, microporous structure.

In a multitude of applications in the fields of chemistry, biochemistry, or medicine, the problem arises of separating gaseous components from liquids or adding such
20 components to the liquids. For such gas exchange processes, there is increasing use of membranes that serve as a separation membrane between the respective liquid, from which a gaseous component is to be separated or to which a gaseous component is to be added, and a fluid that serves to absorb or release this gaseous component. An important application of membrane-based gas exchange processes
25 in the medical field is for oxygenators, also called artificial lungs. In these oxygenators, which are used in open-heart operations, for example, oxygenation of blood and removal of carbon dioxide from the blood take place. Generally, bundles of hollow-fiber membranes are used for such oxygenators.

30 In order to provide the blood with sufficient oxygen and at the same time to remove carbon dioxide from the blood to a sufficient extent, the membranes must ensure a

high degree of gas transport: a sufficient amount of oxygen must be transferred from the gas side of the membrane to the blood side and, conversely, a sufficient amount of carbon dioxide from the blood side of the membrane to the gas side, i.e., the gas flow or gas transfer rates, expressed as the gas volume transported per unit of time and membrane surface area from one membrane side to the other, must be high. A decisive influence on the transfer rates is exerted by the porosity of the membrane, since only in the case of sufficiently high porosity can adequate transfer rates be attained. Membranes for oxygenation are e.g. described in EP-A 0 299 381, US 6,409,921 or US 6,497,752.

5

To keep the stress level low and relax the patient, the patient has to be asleep for many medical procedures. Thus, during a surgical intervention anesthetic agents, i.e. an anesthetic gas mixture is added to the breathing air in order to sedate the patient. Since these anesthetic gases are expensive, the anesthetic gas-air mixture is circulated.

10

Anesthetic circuit systems wherein anesthetic agent is partially re-used after being delivered to the patient are known in the art. The benefit is that less anesthetic agent is used. This is financially beneficial due to the relatively high cost of most anesthetic agents. The use of less anesthetic agents may also be good for the environment since some anesthetic agents, such as the halogenated hydrocarbon sevoflurane, for example, are greenhouse fluids.

15

Carbon dioxide is formed in the cell and is released through the alveoli of the lungs during expiration at a level of around 5% of the expiratory fluid mixture. The concentration at the end of expiration is called the end tidal carbon dioxide value. The inspiratory level of carbon dioxide is normally well below 0.5%. Having excessive levels of carbon dioxide in the blood of the patient will decrease the pH value of the blood (acidosis) and will, if not treated properly, affect the patient's brain activity and may eventually lead to unconsciousness and death.

20

25

30

When the patient inhales the anesthetic agent in a fluid mixture, the anesthetic agent passes through the alveoli of the lungs into the patient's blood. The patient exhales a fluid mixture comprising, among other components, exhaled anesthetic, exhaled oxygen O₂ and exhaled carbon dioxide CO₂. Due to the operation of the human's
5 lungs, the carbon dioxide content of the exhaled fluid mixture is higher than that of the inhaled fluid mixture. Furthermore, the oxygen content of the exhaled fluid mixture is lower than that of the inhaled fluid mixture. To be able to re-use the fluid mixture (containing the exhaled anesthetic fluid), the carbon dioxide of the exhaled fluid mixture must be lowered to levels suitable for re-inhalation.

10

Anesthetic circuits aimed at decreasing the amount of carbon dioxide fluid re-inhaled by the patient are known in the art. Some in the industry have focused on decreasing the carbon dioxide content in the exhaled mixture, along with trying to preserve exhaled oxygen and exhaled molecular anesthetic agent within the anesthetic circuit
15 for re-inhalation. Their desire to preserve exhaled oxygen fluid is premised on the notion that oxygen needs to be provided as part of the inhaled mixture in an appropriate level to keep the oxygen saturation in the patient's blood high enough to allow for proper metabolism. Many publications focus on separating or binding the CO₂ specifically and therefore separate it from the fluid mixture containing the
20 anesthetic agent.

Some conventional anesthetic circuits use carbon dioxide absorbers to reduce exhaled carbon dioxide within the anesthetic circuit. In some cases, soda lime or baralyme, for example, are used. Sevoflurane and other anesthetic vapours can
25 react with these carbon dioxide absorbers to produce harmful chemicals such as compound A. Compound A has been found to have negative effects such as nephro and cerebo toxic effects.

In order to circumvent the problems arising from usage of absorber materials for removal of exhaled CO₂ an anesthetic circuit for treating a patient has been
30 proposed which comprises a polymeric hollow fiber membrane which is at least

partially impervious to the exhaled molecular anesthetic agent but is pervious to oxygen and to carbon dioxide (see WO 2012/174649; WO 2014/094139).

The hollow fiber membranes used in these anesthetic circuits may be made of a polymethylpentene and have an asymmetric structure with a porous support layer and a denser outer layer. For example a hollow fiber membrane sold under the trademark OXYPLUS® (3M Corporation) has been used, which was contained in an QUADROX-D® oxygenator (Maquet Cardiopulmonary AG).

While it was found that removal of CO₂ and the O₂ balance could be effected sufficiently with these oxygenators containing OXYPLUS® membranes, still some amounts of anesthetic agents passed through the membrane. On the other hand, a similar membrane was used in examples of WO 2012/174649 sold under the tradename ULTRAPHOBIC (3M Corporation) which showed good retention of anesthetic agents but for which the transfer of CO₂ and O₂ across the membrane wall was insufficient.

It is therefore an object of the present invention to provide a membrane which has improved gas permeance characteristics and which could be used in an anesthetic circuit. It is a further object of the invention to provide a process for manufacturing such membrane.

The object is met by an integrally asymmetrical hollow fiber membrane for retention of anesthetic agents, which membrane is composed primarily of a poly(4-methyl-1-pentene) and has an inner surface facing towards its lumen, an outer surface facing outwards, a support layer with a sponge-like, open-pored, microporous structure between inner surface and outer surface and adjacent to this support layer on the outer surface a separation layer with denser structure, wherein the support layer is free of macrovoids and the pores in the support layer are on average essentially isotropic, characterized in that

- the separation layer has a thickness in the range between 1,0 and 3,5 µm and,

- that the membrane has a permeance for CO₂ of 20-60 mol/(h·m²·bar), a gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ of at least 5 and a selectivity CO₂ / molecular anesthetic agent of at least 150
- and that the membrane has a porosity in the range of greater than 35% to less than 50% by volume.

These membranes find excellent application in anesthetic circuits for treating patients, wherein the overall structure of the membrane allows for a high CO₂ permeance, i.e. for a good transport of carbon dioxide over the membrane wall, and thus makes possible sufficiently high removal rates for CO₂ from the exhaled fluid mixture in an anesthetic circuit. On the other hand, the high selectivity CO₂ / anesthetic agents of at least 150, which is caused by the structure of the separation layer of the membrane of the invention ensures a very high retention of anesthetic agents by the membrane, so that the anesthetic agents added into the fluid mixture inhaled by the patient nearly quantitatively remain in the anesthetic circuit. Therefore, another aspect of the present invention is the use of the integrally asymmetrical hydrophobic hollow fiber membrane of the invention in an anesthetic circuit. In a preferred embodiment the present membrane has a selectivity CO₂ / anesthetic agent in the range of 220 to 1000. Particularly preferred is a selectivity CO₂ / anesthetic agent in the range of 400 to 1000. The values and ranges for the selectivity CO₂ / anesthetic agent are in particular valid for sevoflurane as anesthetic agent.

The anesthetic agent is understood to be a molecular anesthetic agent and may comprise a polyhalogenated ether. More particular, the molecular anesthetic agent may include at least one of sevoflurane, isoflurane or desflurane. The molecular anesthetic agent may preferably have a molecular weight of greater than 168 g/mol.

The present hollow fiber membrane has an asymmetric structure in that it has on one side of the membrane wall a dense separation layer covering a coarser pored support layer. Within the context of the present invention, an integrally asymmetrical

membrane is understood to be one in which the separation and support layers consist of the same material and have been formed together directly during membrane production and both layers are integrally joined with each other as a result. In the transition from the separation layer to the support layer, there is merely
5 a change with respect to the membrane structure. Contrasting with this are composite membranes, for example, which have a multilayer structure formed by applying, in a separate process step, a dense layer as a separation layer on a porous, often microporous support layer or support membrane. The result is that the materials constituting the support and separation layers also have different
10 properties in the case of composite membranes.

Due to its structure, the present hollow fiber membrane is distinguished by high gas flow rates and high gas transfer rates or gas permeances, respectively, while maintaining high levels of safety with respect to a permeation of anesthetic agents.
15 To achieve this, the volume porosity of the present membrane has to be adjusted in a rather narrow range between 35 and 50% by volume, whereby the volume porosity is determined substantially by the structure of the support layer. Preferably the membrane has a volume porosity in the range from 40% to 50% by volume.

20 On the other hand, it is necessary for the present membrane to have a defined separation layer with a dense structure which allows transport of oxygen and carbon dioxide but safely retains anesthetic gases. It has been found that in order to achieve safe retention of anesthetic agents, the separation layer needs to have a minimum thickness of 1.0 μm while for a sufficient transport of oxygen and carbon dioxide the
25 thickness of the separation layer should not exceed 3.5 μm . Preferably, the separation layer of the present hollow fiber membrane may have a thickness between 1.0 μm and 2.0 μm and more preferably a thickness between 1.0 and 1.8 μm . In a further preferred embodiment of the present membrane, the membrane structure changes abruptly in the transition from the separation to the support layer,
30 i.e., the membrane structure changes substantially transition-free and suddenly without gradual change from the microporous support structure to the separation

layer. The thickness of the separation layer can be determined for the membranes of the invention in a simple manner by measuring the layer using fracture images generated by scanning electronic microscopy or by ultrathin-section characterizations using transmission electron microscopy.

5

The support layer of the membrane of the invention may have various structures. In one embodiment of the membrane of the invention, the support layer may have a sponge-like, cellular and open-pored structure, in which the pores can be described as enveloped microcells that are interconnected by channels, smaller pores, or passages. In another embodiment of the membrane of the invention, the support layer may have a non-cellular structure, in which the polymer phase and the pores form interpenetrating network structures. In any case, however, the support layer is free of macrovoids, i.e., free of such pores often referred to in the literature as finger pores or caverns.

15

The pores of the support layer can have any geometry and be, for example, of elongated, cylindrical, rounded shape, or also have a more or less irregular shape. In accordance with the invention, the pores in the support layer are on average substantially isotropic. This is understood to mean that, although the individual pores can also have an elongated shape, the pores on average in all spatial directions have substantially the same extension, whereby deviations of up to 20% can exist between the extensions in the individual spatial directions.

20

The membrane of the invention has a separation layer on its outer surface. In a preferred embodiment the membrane of the invention has on its inner surface facing the lumen an open-pored, network-like structure with approximately circular openings. Approximately circular openings are understood to be openings in which the ratio of the major axis to the minor axis does not exceed 2:1. Due to their open-pored structure, such membranes have on their one side a comparatively small resistance to gas flow, for example.

30

The separation layer influences the gas flow and gas transfer rates. It also influences whether and how well various gases in a gas mixture can be separated from one another, i.e., the gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$, for example.

5 In the dense separation layer of the present membrane, the gas transfer or gas flow takes place via solution diffusion. The tightness of the separation layer and its suitability in particular for gas transfer can often not be evaluated with sufficient reliability solely on the basis of visual inspection, using a scanning electron microscope for example. In this case, not only the size of existing pores or in general
10 structural defects such as fissures but also their number play a role. However, for membranes having a dense separation layer, the characteristics of the separation layer can only be evaluated by examining the gas permeation and gas flow through the membrane as well as the gas separation factors.

15 It is well known that the general principles of gas transport in polymer membranes depend on the pore size in the membrane. In membranes with a dense separation layer, the gas permeates through this membrane via solution diffusion mechanisms, i.e. gas permeation through nonporous membranes has two components: solution and diffusion. Components in the feed gas dissolve in the polymeric membrane
20 material at a high pressure and then diffuse down their concentration gradient through the membrane to the permeate side of the membrane. Membrane selectivity is determined by combining the differences in component solubility and diffusivity.

The solution-diffusion model assumes that the pressure across the membrane is
25 constant at the feed pressure (p_0), so diffusion is driven by concentration differences. The model is able to describe permeability as a function of solubility and diffusivity. Henry's Law relates the concentration of a solute in the membrane to the bulk partial pressure applied to the membrane and accounts for the discontinuity between the bulk and membrane concentration. It is therefore possible to express
30 the flux, J_i , in terms of partial pressures incorporating the solubility coefficient per Equation 1:

$$J_i = \frac{D_i S_i}{l} (p_{i0} - p_{il}) \quad (1)$$

Where S_i is the solubility coefficient of component i ($\text{mol m}^{-2} \text{bar}^{-2}$), relating the partial pressure of the component to the concentration in the membrane phase, and p_{i0} and p_{il} are the partial pressures (bar) of component i at the feed and permeate membrane interfaces, respectively.

The permeability, P_i , describes the flux, J_i , normalized to time, area, and driving force. P_i is the product of the solubility coefficient, S_i , and diffusion coefficient, D_i , in the membrane. Since it is often difficult to define the membrane thickness in a consistent manner, especially for asymmetric membranes, where the proportional thickness of the support layer and the dense skin can vary, the permeability and membrane thickness are often lumped together into a single parameter referred to as the permeance K_i . The permeance can be directly calculated by normalizing the flux for the driving force, using Equation 2:

$$K_i = \frac{P_i}{l} = \frac{D_i S_i}{l} = \frac{J_i}{p_{i0} - p_{il}} \quad (2)$$

It is usually possible to assume that the component partial pressures at each membrane interface (0 and l) are equal to the average partial pressure of the feed and permeate, respectively. The membranes of this application are hollow fiber membranes with the dense layer at the outside.

During characterization, the feed is going to be on the lumen side and the permeate will be on the shell side of the module containing these fibers. In this case, the permeance can be calculated by dividing the flux J_i of component i across the membrane by the average partial pressure difference of that component between the feed and the permeate side. On the shell-side, the permeate is assumed to be perfectly mixed, so its partial pressures are assumed to be equal to the measured outlet partial pressure.

In this case, the permeance can be calculated using Equation 3, where the partial pressure driving force is estimated using Equation 4:

$$K_i = \frac{J_i}{\Delta p_{i,LM}} \quad (3)$$

$$\Delta p_{i,LM} = \frac{(y_{if,in}P_f - y_{iP}P_P) - (y_{if,out}P_f - y_{iP}P_P)}{\ln(y_{if,in}P_f - y_{iP}P_P / y_{if,out}P_f - y_{iP}P_P)} = \frac{P_f(y_{if,in} - y_{if,out})}{\ln(y_{if,in}P_f - y_{iP}P_P / y_{if,out}P_f - y_{iP}P_P)} \quad (4)$$

5

In addition to permeability and permeance, membrane selectivity is an additional intrinsic membrane property used for characterization. Membrane selectivity (α_{ij}) is defined as the ratio of the permeability or permeance of two components (i and j) through a membrane, per Equation 5:

$$\alpha_{ij} = \frac{K_i}{K_j} = \frac{P_i}{P_j} \quad (5)$$

10

Selectivity can be reported as a ratio of pure gas permeance, or when measured in a mixture of the several components, as the ratio of permeance of the gas components in the mixture.

15 To ensure the gas flow characteristic of the present invention and to ensure a high integrity of the separation layer, the hollow fiber membrane, therefore, preferably may have a gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ of at least 8 and more preferably of at least 10.

20 Despite the presence of a dense separating layer the membrane of the invention exhibits a high permeance for O_2 and CO_2 . In particular the permeance with respect to CO_2 is an important factor in anesthetic circuits in order to remove CO_2 from the patient's exhaled fluid mixture. The O_2 and CO_2 permeances are thus regarded as a measure for the gas transfer capacity of the membrane, in each case with respect
25 to the permeate side being held at atmospheric pressure. The membrane may have a permeance for CO_2 of 20-60 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$ and preferably of 25-40 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$. In a further preferred embodiment the membrane may have a O_2

permeance of at least $10 \text{ mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$ and more preferably of at least $15 \text{ mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$.

The hollow-fiber membrane preferably has an outside diameter between 200 and
5 500 μm , especially preferably between 300 and 400 μm . A wall thickness of the hollow-fiber membrane between 50 and 150 μm is advantageous, and a thickness between 50 and 100 μm is especially advantageous.

The hollow-fiber membrane according to the invention can be produced by means
10 of a method in which the membrane formation takes place via a thermally induced phase separation process.

The object of the invention is further met by a process for producing the integrally
asymmetrical hydrophobic hollow fiber membrane of the invention composed
15 primarily of a poly(4-methyl-1-pentene) and having an inner surface facing towards its lumen, an outer surface facing outwards, the membrane having between inner surface and outer surface a support layer with a sponge-like, open-pored, microporous structure and adjacent to this support layer on the outer surface a separation layer with denser structure, wherein the support layer is free of
20 macrovoids and the pores in the support layer are on average essentially isotropic, the process comprising at least the steps of:

a) preparing a homogeneous solution of a polymer component consisting of a
poly(4-methyl-1-pentene) in a solvent system containing a component A and a
25 component B that are liquid and miscible with each other at the dissolving temperature, whereby the employed mixture of the polymer component and components A and B has a critical demixing temperature and a solidification temperature and has a miscibility gap in the liquid state of aggregation below the critical demixing temperature, whereby a strong solvent for the polymer
30 component is selected for component A, for which the demixing temperature of a solution of 25% by weight of the polymer component in this solvent is at least

10% below the melting point of the pure polymer component, wherein demixing temperature and melting point are measured in °C, and component B raises the demixing temperature of a solution consisting of the polymer component and component A, wherein component B is a weak non-solvent for the polymer component, which does not dissolve the polymer component to form a homogeneous solution when heated to the boiling point of component B and for which the demixing temperature of a system consisting of 25% by weight of the polymer component, 10% by weight of the weak non-solvent, and 65% by weight of component A, used as the solvent, is at most 10% above the demixing temperature of a system consisting of 25% by weight of the polymer component and 75% by weight of component A, wherein the temperatures are measured in °C,

b) rendering the solution to form a hollow fiber, with outer and inner surfaces, in a die having a temperature above the critical demixing temperature,

c) cooling of the hollow fiber using a liquid cooling medium having an entrance surface, which cooling medium does not dissolve the polymer component or react chemically with it at temperatures up to the die temperature and is tempered to a cooling temperature below the solidification temperature, wherein the cooling medium is a homogeneous, single-phase liquid at the cooling temperature and the cooling is done at such a rate that a thermodynamic non-equilibrium liquid-liquid phase separation into a high-polymer-content phase and a low-polymer content phase takes place and solidification of the high-polymer-content phase subsequently occurs when the temperature falls below the solidification temperature,

d) possibly removing components A and B from the hollow fiber, characterized in that the concentration of the polymer component in the homogeneous solution is in the range from 42.5 to 45.8% by weight and the concentration of the solvent system in the range from 57.5 to 54.2% by weight and

that the hollow fiber leaving the die runs through a gap between the exit surface of the die and the surface of the cooling medium before entering the cooling medium, wherein the gap has a length in the range from 5 to 30 mm.

5 It has been found to be essential in the process of the invention to adjust the concentration of the polymer component in the homogeneous solution in a very narrow range from 42.5 to 45.8% by weight in order to obtain a hollow fiber membrane having the required balanced properties with respect to the permeance of O₂ and CO₂ on one hand and of the anesthetic agents on the other hand. In
10 addition, in order to obtain a separation layer having the required properties, is necessary for the hollow fiber exiting the die to travel through a gap before entering the cooling medium. In the process of the invention the gap between the die and the entrance surface of the cooling medium may have a length in the range of 5 to 30 mm. When adjusting the gap length in the required range, hollow fiber membranes
15 with sufficiently dense separation layers are obtained while the separation layer still is sufficiently permeable for CO₂.

The process according to the invention is based on a thermally induced phase separation process with liquid-liquid phase separation. According to the invention,
20 the polymer component and components A and B form a binary system, which in the liquid state of aggregation has a range in which the system is present as a homogeneous solution and a range in which it exhibits a miscibility gap. If such a system is cooled, from the range in which it is present as a homogeneous solution, below the critical demixing or phase separation temperature, liquid-liquid demixing
25 or phase separation into two liquid phases, namely one with a high polymer content and the other with a low polymer content, initially takes place. On further cooling, below the solidification temperature, the high-polymer-content phase solidifies to form a three-dimensional membrane structure. The cooling rate thereby has a substantial influence on the pore structure being created. If the cooling rate is high
30 enough that the liquid-liquid phase separation cannot take place under thermodynamic equilibrium conditions but rather under thermodynamic non-

equilibrium conditions and on the other hand still relatively slowly, the liquid-liquid phase separation occurs approximately concurrently with the formation of a large number of droplets of liquid that are of substantially the same size. The resulting polymer object then has a sponge-like cellular and open-pored microstructure. If the cooling rate is significantly higher, the polymer solidifies before most of the droplets of liquid can form. In this case, network-like microstructures are formed. The variety of such sponge-like microporous structures formed via processes with thermally induced liquid-liquid phase separation are described in detail in US 4,519,909, to the disclosure of which reference is hereby explicitly made, and depicted for example in R.E. Kesting, "Synthetic Polymeric Membranes", John Wiley & Sons, 1985, pp. 261-264.

The employed combinations of the polymer component, component A, and component B, whereby components A and B together form the solvent system, must be convertible jointly into a single homogeneous liquid phase and have a critical demixing temperature below which a phase separation into two liquid phases occurs. This is higher, however, than the demixing temperature of a solution containing equal parts of polymer but only component A as a solvent system. In polymer/component A systems with a miscibility gap in the liquid state of aggregation, the addition of component B therefore raises the critical demixing temperature. Adding component B enables selective control of pore size and pore volume in the porous structures obtained.

For component A, components are to be used that are solvents for the polymer component and in which, when heated at most to the boiling point of this component, this polymer component is dissolved completely to form a homogeneous solution. According to the invention, a solvent must be used as component A for which the demixing temperature of a solution of 25% by weight of the polymer component in this solvent is at least 10% under the melting point of the pure component consisting of the at least one polymer, wherein demixing temperature and melting point are

measured in °C. Within the scope of the present invention, such a solvent is referred to as a strong solvent.

5 The demixing or phase separation temperature can be determined in a simple manner by initially preparing a homogeneous solution of the polymer component in the solvent to be investigated and then heating this solution to a temperature approximately 20°C above the dissolving temperature. This solution is stirred and maintained at this temperature for about 0.5 hours, in order to achieve sufficient homogeneity. Subsequently, the solution is stirred and cooled at a rate of 1°C/min.
10 The phase separation temperature is determined as the temperature at which clouding becomes visible. On further cooling, the phase with high polymer content solidifies at the solidification temperature.

For component B, according to the invention a component is selected that is a weak
15 non-solvent for the polymer component. Non-solvent for the polymer component is understood to mean a component that does not dissolve the polymer component, in a concentration of 1% by weight in the non-solvent, to form a homogeneous solution when heated to at most the boiling point of this non-solvent. In the scope of the present invention, the strength of the non-solvent is assessed on the basis of the
20 difference between the demixing temperature of a system consisting of the polymer component and a strong solvent and the demixing temperature of a corresponding system containing as a solvent system the same solvent and 10% by weight of the non-solvent to be investigated. The polymer concentration in each case is 25% by weight. A weak non-solvent is then understood to be one that leads to an increase
25 in the demixing temperature of at most 8% relative to the demixing temperature of the corresponding system consisting only of solvent and polymer, wherein the temperatures are measured in °C. A strong non-solvent is, by definition, one that leads to an at least 10% increase in the demixing temperature.

30 Component A can also be blended with one or more liquids, in particular other solvents. Component B can also be employed as a mixture with one or more other

components, in particular additional non-solvents. As a result, within the context of the present invention, component A is understood as not only a single component but also a mixture of different solvents, for example two strong solvents or a strong with a weak solvent, as long as the overall action as a strong solvent is maintained.

5 Likewise, component B is also understood to be a mixture of different non-solvents, for example several weak non-solvents, as long as the action as a weak non-solvent is maintained.

The fraction of polymer required for membrane production and the ratio of
10 component A to component B in the solvent system can be determined by generating phase diagrams in simple experiments. Such phase diagrams can be developed using known methods, such as are described in C.A. Smolders, J.J. van Aartsen, A. Steenbergen, *Kolloid-Z. und Z. Polymere*, 243 (1971), pp. 14-20. As a rule, for a given solvent A, the fraction of component B, i.e., weak non-solvent, in
15 the mixture of the polymer component, component A, and component B depends on the strength of the non-solvent, i.e., component B. Preferably, the fraction of component B in the solvent system is 1 to 45% by weight.

In the process according to the invention, the polymer component is a poly(4-methyl-
20 1-pentene). It has been found that poly(4-methyl-1-pentene) has high gas permeability coefficients for O₂ and CO₂ and thus high gas transfer rates or permeances can be realized when using this polymer while maintaining good mechanical properties for the membranes.

25 For components A and B, which jointly form the solvent system, components are to be used that fulfill the stated conditions. For the present process, component A is preferably dioctyl adipate, isopropyl myristate, diphenyl ether, dibenzyl ether, or mixtures thereof. Glycerin triacetate, diethyl phthalate, castor oil, N,N-bis(2-hydroxyethyl)tallow amine, soybean oil, or mixtures thereof have proven
30 advantageous as component B. Especially good results are obtained when glycerin triacetate is used as component B. In a particular preferred embodiment of the

process the solvent system comprises a mixture of dioctyl adipate, glycerin triacetate and castor oil. Membranes produced from this solvent system on one hand show the required characteristics regarding gas transfer rates (permeance) and selectivity but also exhibit good mechanical properties.

5

The polymer fraction of the solution has to be set to the narrow range from 42.5 to 45.8% by weight, and the fraction of the solvent system, consisting of components A and B, to the range from 57.5 to 54.2% by weight. The polymer fraction is preferred to be 43-45.5% by weight and the fraction of components A and B 57-54.5% by weight. If necessary, additional substances such as antioxidants, nucleating agents, fillers and similar substances can be employed as additives to the polymer component, components A and B, or to the polymer solution.

The polymer solution formed from the polymer component and the solvent system is given shape using suitable dies to produce a hollow-fiber membrane. Conventional hollow-fiber dies can be employed.

In the present process for manufacturing the hollow-fiber membranes the polymer solution is extruded through the annular gap of the hollow-fiber die to form a hollow fiber. A fluid is metered through the central bore of the hollow-fiber die that acts as an interior filler for shaping and stabilizing the lumen of the hollow-fiber membrane. The extruded hollow fiber leaving the hollow-fiber die at the die exit surface then exhibits a surface facing the lumen, the interior surface, and a surface facing away from the lumen, the exterior surface, separated from the interior surface by the wall of the hollow fiber.

The interior filler employed can be in gaseous or liquid form. When using a liquid as the interior filler, a liquid must be selected that substantially does not dissolve the polymer component in the shaped polymer solution below the critical demixing temperature of the polymer solution. To achieve an open-pored structure on the interior surface, interior fillers are preferably used that are solvents for the at least

one polymer used, whereby the previously cited condition must be observed, and/or temperatures of the interior filler are set that are in the vicinity of the polymer solution temperature. The interior filler can be miscible with the solvent system. Preferably the interior filler is gaseous; it can be air, a vaporous material, or preferably nitrogen
5 or other inert gases.

After shaping, the hollow fiber is cooled using a liquid cooling medium, so that a thermodynamic non-equilibrium liquid-liquid phase separation occurs in the hollow fiber, i.e., in the shaped polymer solution, and the polymer structure subsequently
10 solidifies and hardens. In this process, the liquid cooling medium has been tempered to a temperature below the solidification temperature. According to the invention, in order to produce the desired integrally asymmetrical membrane with separation layer, the cooling medium must be one that does not dissolve the polymer component and does not chemically react with it, even when the medium is heated
15 to the die temperature. The use of such a cooling medium is decisive for the formation of a separation layer. Such a requirement placed on the cooling medium rules out, for example, the use as a cooling medium of the mixture of components A and B employed as the solvent system. Although such a system would not dissolve the polymer component at the cooling temperature, the polymer component
20 forms a homogeneous solution at the die temperature, as previously noted.

In the process of the invention the exit surface of the die and the surface of the cooling medium are spatially separated by a gap, which is transited by the extruded hollow fiber prior to contact with the liquid cooling medium and which may have a
25 length in the range from 5 to 30 mm. In a preferred embodiment of the present process the gap may have a length in the range of 15 to 25 mm. As mentioned above, for of a separation layer having the required characteristics it is decisive for the extruded hollow fiber to run through a gap between exit surface of the hollow fiber die and the entrance surface of the liquid cooling medium. The gap preferably may
30 be an air gap, which at least partially may be heated at the upper end by the hollow fiber forming die. It is believed that formation of a separation layer on the outside

surface of the hollow fiber is already initiated in the gap between die and surface of the cooling medium. Only in case the hollow fiber travels through a gap having a length in the range from 5 to 30 mm and preferably in the range of 15 to 25 mm a hollow fiber membrane is obtained after cooling having a sufficiently dense separation layer.

It is preferred for the liquid used as the cooling medium to be a non-solvent for the polymer component, i.e., it does not dissolve the polymer component to form a homogeneous solution when heated to at most the boiling point of the cooling medium. The liquid used as the cooling medium can also contain a component that is a solvent for the polymer component, or it can also be a mixture of different non-solvents, as long as it overall does not dissolve the polymer component. It is observed in this case that the degree of non-solvent character of the cooling medium influences the tightness of the separation layer being formed. In an especially preferred embodiment of the process according to the invention, therefore, a liquid is used as a cooling medium that is a strong non-solvent for the polymer component. Concerning the definitions of non-solvent and strong non-solvent, reference is made to the previous discussion in conjunction with component B. Preferably, the cooling medium at the cooling temperature is a homogeneous, single-phase liquid. This ensures production of membranes with especially homogeneous surface structures. The liquid cooling medium can be one that is miscible with the solvent system to form a homogeneous solution or one that does not dissolve the components forming the solvent system.

To initiate a thermodynamic non-equilibrium liquid-liquid phase separation, the temperature of the cooling medium must be significantly below the critical demixing temperature or phase separation temperature of the polymer solution used and furthermore below the solidification temperature in order to solidify the phase with high polymer content. In this case, the formation of the separation layer is promoted when there is as great a difference as possible between the demixing temperature and the temperature of the cooling medium. The cooling medium preferably has a

temperature at least 100°C below the phase separation temperature, and especially preferably a temperature that is at least 150°C below the phase separation temperature. It is particularly advantageous if the temperature of the cooling medium in this case is under 50°C. In individual cases, cooling to temperatures below ambient temperature can be required. It is also possible for cooling to take place in several steps.

The liquid cooling medium is preferably in a shaft or spinning tube which the shaped object passes through for cooling purposes. The cooling medium and shaped object are generally fed in the same direction through the shaft or spinning tube. The shaped object and cooling medium can be fed at the same or different linear speeds through the spinning tube, whereby, depending on the requirement, either the shaped object or the cooling medium can have the higher linear speed. Such process variants are described in US 4,564,488 or US 4,666,607, for example.

After cooling and hardening of the polymer structure, components A and B are usually removed from the membrane structure so produced. Removal can be performed, for example, by extraction. Preferably, extraction agents are used that do not dissolve the polymer or polymers but are miscible with components A and B. Subsequent drying at elevated temperatures can be necessary to remove the extraction agent from the membrane. Suitable extraction agents are acetone, methanol, ethanol, and preferably isopropanol.

The invention will now be described in more detail with reference to the following examples and figures:

The following methods were employed to characterize the membranes obtained:

Determination of the volume porosity:

A sample of at least 0.5 g of the membrane to be examined is weighed in a dry state. The membrane sample is then placed for 24 hours into a liquid that wets the

membrane but does not cause it to swell, such that the liquid penetrates into all pores. This can be detected visually in that the membrane sample is transformed from an opaque to a glassy, transparent state. The membrane sample is then removed from the liquid, liquid adhering to the sample removed by centrifugation at
 5 about 1800 g, and the mass of the thus pretreated wet, i.e., liquid-filled, membrane, determined.

The volume porosity in % is determined according to the following formula 6:

$$\text{Volume porosity [\%]} = 100 \cdot \frac{(m_{\text{wet}} - m_{\text{dry}})/\rho_{\text{liq.}}}{(m_{\text{wet}} - m_{\text{dry}})/\rho_{\text{liq.}} + m_{\text{dry}}/\rho_{\text{polymer}}} \quad (6)$$

10

where

m_{wet} = weight of the wet, liquid-filled membrane sample

m_{dry} = weight of the dry membrane sample

$\rho_{\text{liq.}}$ = density of the liquid used

15 ρ_{polymer} = density of the membrane polymer

Determination of permeance and selectivity:

Gases and gas mixtures:

20 For determination of membrane permeance and selectivity the following gases and gas mixtures were employed:

A certified mixture of 5% CO₂ balanced in O₂ was used as a carrier gas in the ternary gas mixture experiments and for calibrating the mass spectrometer. A certified calibration gas mixture of He, O₂ and N₂ was also used to calibrate the mass
 25 spectrometer. The gases and gas mixtures used are listed in Table 1:

Table 1:

Gas	Specification	Supplier
CO ₂	USP grade, 99.5% pure, DIN: 02014459	Praxair, Mississauga, ON, CAN
O ₂	USP grade, 99.99% pure, DIN: 02014408	Praxair, Mississauga, ON, CAN
N ₂		Air Liquide, Dartmouth, NS, CAN
5% CO ₂ balanced in O ₂	USP grade, 99.5% pure, DIN: 02014432	Praxair, Mississauga, ON, CAN
He, O ₂ and N ₂	SPG-3MX0021714	Air Liquide, Dartmouth, NS, CAN

Sevoflurane (Abbvie, North Chicago, Illinois, United States), Desflurane and Isoflurane (both from Baxter Corporation, Deerfield, Illinois, United States) were administered with anaesthesia vapourizers (Draeger, Lübeck, Germany). The permeation apparatus was assembled with plastic Legris 1/4-inch vacuum rated PTFE fittings and 1/4-inch polyethylene tubing, as well as TruWave 1/8-inch tubing and fittings for the permeate line and mass spectrometer sampling point.

Mass Spectrometer

Gas concentrations or gas compositions for determination of permeance and selectivity were measured using a mass Spectrometer. A quadrupole mass spectrometer (Omnistar Model PTM81217131, Pfeiffer Vacuum, Aßlar, Germany) was used to measure the gas composition of the feed, retentate streams as well as the permeate streams for the mixed-gas tests. The mass spectrometer was controlled through Pfeiffer Vacuum's Quadera software (v4.50.004). Mass spectrometer operation, data analysis, display and storage were all controlled via Quadera. It was operated using Secondary Electron Multiplier (SEM) ion detection to achieve a higher resolution and to enable accurate detection at low concentrations. The same operating conditions were used for all of these experiments (SEM voltage of 910 V, Ion Current of $5.1 \cdot 10^{-9}$ A, Spectral Resolution of 50 and a dwell of one second).

The mass spectrometer was calibrated for mass specific concentration determination per Pfeiffer Vacuum's recommended calibration procedure. An offset calibration was performed to eliminate any inherent offset of the measured SEM signal. A mass scale adjust calibration was then conducted to tune the mass scale to adjust the measured value of each mass of interest to an integer value. A background determination calibration was then performed to identify any mass peaks from residual gases that were not associated with the gases being measured. Background spectra from this calibration were subtracted from subsequent measurements. The final calibration was the gas specific calibration, where ion peaks are translated to concentration by the gas specific calibration, which entails the assignment of compounds to mass peaks. A calibration factor library was then constructed using certified calibration gas mixtures. The mass spectrometer calibration was maintained throughout the course of the experiment testing.

Anaesthesia calibration mixtures were mixed by manually injecting a defined amount of liquid Sevoflurane, Desflurane, or Isoflurane into a syringe filled with oxygen and agitating it to vapourise the liquid. The composition was calculated using the compound properties and the ideal gas law. The mixture was then used to calibrate the mass spectrometer. The concentrations supplied by the vaporizers were then verified with the calibrated device.

Determination of permeation characteristics:

Permeation characteristics of the membranes in the modules were measured using a variation of the constant-pressure variable-volume method.

Fig.1 shows a schematic of the experimental system.

The feed gas flow rate was controlled using a needle valve and flow was measured using a glass tube flow meter (Scott Specialty Gases, Plumsteadville, PA, USA) and the feed pressure using an analogue pressure gauge (Speidel Keller, Jungingen, Germany, accuracy: ± 5 mmHg or ~ 6.67 mbar) connected to the lumen outlet stream. The feed pressure on the lumen side was held constant at 1.2 bar for each

experiment. The permeate pressure on the shell side was atmospheric. One port of the shell side of the module was plugged and the other port was fed through a 3-way valve either to a modified, horizontally placed glass pipette (Fischer Scientific, 5 mL total volume) for flow measurements or to the mass spectrometer for concentration determination.

To calculate the mean flow rate, the pipette was filled with water prior to each trial and time measurements were taken at 0.5 mL intervals as the permeated gas displaced the water. Immediately following the volumetric flow rate measurement, the permeate was then fed to the mass spectrometer sampling port and the gas composition only for the mixed gas experiments. Feed gas concentrations were measured when both shell-side ports on the module were plugged. The gas composition was measured from the retentate port of the module. The system was purged with oxygen between each trial.

Pure Gas Permeation Measurements

The pure gas permeance of the membranes was determined for pure carbon dioxide (CO₂), oxygen (O₂), and nitrogen (N₂) supplied at 1.2 bar. Once the concentration of the gases stabilized, the permeate line was connected to the pipette setup. Four time readings were then measured every 0.5 mL as the permeate displaced the water. These readings were averaged and counted for one trial. A minimum of three trials were performed for each module at each set of operating conditions. A minimum of three trials were performed for each module at each set of operating conditions. The pure gas permeance was calculated according to Equation 7:

$$K_i^P = \frac{Q}{A(p_f - p_p)} \quad (7)$$

Where Q is the permeate molar flow rate (mol/h), p_f is the absolute pressure of the feed (bar), p_p is the absolute pressure of the permeate (bar), and A is the inside active membrane area (m²). Permeance is reported in units of mol/h/m²/bar. The

pure gas selectivity (α_{ij}^P) was calculated based on the ratio of the mean permeance of two pure gases i and j per Equation 8:

$$\alpha_{ij}^P = \frac{K_i^P}{K_j^P} \quad (8)$$

Where K_i^P and K_j^P are the pure gas permeances for components i and j, respectively.

5

Mixed Gas Permeation Measurements

The mixed gas permeation procedure was similar to that of the pure gas system but also required concentration measurements of the permeate. The feed and retentate compositions were determined as described above. In addition, following the flow measurements, the permeate was directed to the mass spectrometer for determination of the permeate composition.

Anaesthetic vapour concentrations for the experiments were chosen around their Minimum Alveolar Concentration (MAC). The MAC is a measure of potency of the anaesthesia gas and is defined as the minimum concentration of vapour required to immobilize 50% of patients. The MAC for Sevoflurane, Desflurane and Isoflurane is defined as 2.13%, 6.0% and 1.13% respectively. The vapour experiments were conducted with vapour concentrations at the MAC for each vapour. This set of experiments was performed near clinically relevant operating conditions, at room temperature and low feed pressure (1.2 bar) with either Sevoflurane, Isoflurane or Desflurane at their MAC mixed into a 5% carbon dioxide/oxygen gas mixture to mimic exhalation during anaesthesia administration. Three modules of each membrane type were used and three runs of each module were performed for a total of n = 9 trials for Sevoflurane, Isoflurane and Desflurane.

25

The mixed gas tests entailed monitoring the feed, retentate and permeate gas composition with the mass spectrometer, in addition to the flow rate. The permeances of the mixed gas components were calculated using Equation 9:

$$K_i^M = \frac{y_p Q}{A \Delta p_{i,ave}} \quad (9)$$

The log-mean driving force (Equation 4) was used to compute $\Delta P_{i,ave}$. The mixed gas selectivity, α^M , was calculated using the permeance of two components i and j in a gas mixture per Equation 10:

$$\alpha_{ij}^M = \frac{K_i^M}{K_j^M} \quad (10)$$

Examples 1 to 3 and Comparative Examples 1a, 1b, 2 and 3:

In the Examples 1 to 3 and the Comparative Examples 1a, 1b, 2 and 3, the membranes were manufactured according to the following procedure:

Poly(4-methyl-1-pentene) (TPX DX845) as polymer component was dissolved in a nitrogen atmosphere in a container with stirrer at a temperature of 260°C in a solvent system consisting of 70% by weight dioctyl adipate, 20% by weight glycerin triacetate, and 10% by weight castor oil. The concentrations of polymer and solvent system used in Examples 1 to 3 and in Comparative Examples 1a, 1b, 2 and 3 are listed in Table 1.

After degassing, the resulting clear and homogeneous solution was fed with a gear pump to a hollow-fiber die with an annular-gap outside diameter of 1.2 mm, which had been heated to 248°C, and extruded to form a hollow fiber. Nitrogen was metered into the lumen of the hollow fiber through the interior bore of the hollow-fiber die. After an air section of 24 mm, the hollow fiber passed through an approx. 1 m long spinning tube, through which glycerin triacetate, tempered to ambient temperature, flowed as a cooling medium. The hollow fiber, solidified as a result of the cooling process in the spinning tube, was drawn off from the spinning tube at a rate of 72 m/min, wound onto a spool, subsequently extracted with isopropanol, and then dried at approx. 120°C.

Hollow-fiber membranes were obtained with an inner diameter of about 200 μm and a wall thickness of about 90 μm , for which no pores were observable on its exterior surface in a scanning-electron-microscopic (SEM) image even at 60000x magnification. The interior surface facing the lumen had an open-pored, network-like structure with approximately circular openings. The sponge-like, open-pored, microporous support structure is covered by an approx. 1.5-2.0 μm thick separation layer.

Table 1:

Membrane		Comp. Ex. 1a	Comp. Ex. 1b	Exempl. 1	Exempl. 2	Exempl. 3	Comp. Ex. 2	Comp. Ex. 3
Polymer concentr.	(wt.%)	46.0	46.0	45.8	45.5	45.0	42.5	41.0
Solvent system concentr.	(wt.%)	54.0	54.0	54.2	54.5	55.0	57.5	59.0
Solvent system/polymer ratio		1,17	1,17	1,18	1,20	1,22	1,35	1,44
Fiber wall thickness	(μm)	90	90	90	90	90	90	90
Fiber internal diameter	(μm)	200	200	200	200	200	200	200
Active inside area module	(cm^2)	24	26	26	26	26	26	26
Active outside area module	(cm^2)	45	49	49	49	49	49	49
Module filling degree	%	20.00	20.06	20.06	20.06	20.06	20.06	20.06

With the membranes of each example and comparative example test modules were prepared for testing the properties of the membranes. For this purpose, a minimum of three modules of each membrane type was produced by arranging the hollow fiber membranes in a cylindrical housing and potting the ends of the hollow fiber membranes in tube shells made from polyurethane. The lumina of the hollow fiber membranes were in fluid connection with a feed inlet and a feed outlet, respectively. The space in the module surrounding the hollow fiber membranes was in fluid connection with a permeate outlet.

Details of the membrane modules are listed in Table 2.

For the membranes of each example and comparative example the permeance for CO₂, O₂, and N₂, the gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ and the selectivity CO₂/anesthetic agents was measured according to the test methods described above.

The pure gas permeances for carbon dioxide (CO₂), oxygen (O₂) and nitrogen (N₂) are listed in Table 3 and are shown in Figure 2. The property of most interest for the intended application is the carbon dioxide permeance. In addition, the permeabilities of the three gases are presented in Table 2 for the examples and the comparative examples, wherein the permeabilities are calculated on the basis of the respective permeances by multiplying the permeances by the membrane thickness (fiber wall thickness = 90 μm).

Table 3:

	K_i (mol / m ² / bar / h)			P_{ip} (10 ³ mol cm / m ² / bar / h)			Selectivity α_{ij}		
	CO ₂	N ₂	O ₂	CO ₂	N ₂	O ₂	CO ₂ /O ₂	O ₂ /N ₂	CO ₂ /N ₂
Example 1	23.1	1.6	10.7	208	14	96	2.2	6.9	15.0
Example 2	32.3	3.0	12.3	291	27	111	2.6	4.2	10.9
Example 3	31.8	2.7	14.9	286	24	134	2.1	5.7	12.1
Comp. Ex. 1a	16.7	2.3	7.1	150	21	64	2.3	3.1	7.2
Comp. Ex. 1b	19.8	1.7	7,8	178	15	71	2.5	4.6	11.5
Comp. Ex. 2	88.6	10,1	36.4	797	91	328	2.4	3.6	8.8
Comp. Ex. 3	110.9	10.6	42.2	998	95	380	2.6	4.0	10.5

For the membranes of each example and comparative example mixed gas experiments were performed, i.e. experiments with gas mixtures containing either Sevoflurane (2.0 Vol.-%) , Isoflurane (6.13 Vol.-%), or Desflurane (1.13 Vol.-%) with a balance of 5 Vol.-% CO₂ in O₂ and the CO₂ permeance, K_{CO₂} (in (mol/m²/bar/h)), in these mixtures was compared to the permeance K_{CO₂} of pure CO₂ as determined in the pure gas experiments (see above). The results obtained are listed in Table 4 and shown in Figure 3.

Table 4:

	K _{CO₂} (Pure CO ₂)	K _{CO₂} (CO ₂ /O ₂ /Sevo)	K _{CO₂} (CO ₂ /O ₂ /Iso)	K _{CO₂} (CO ₂ /O ₂ /Des)
Example 1	23,1	15,8	---	---
Example 2	32,3	33,1	11,4	25,2
Example 3	31,8	23,9	10	40,5
Comp. Example 1a	16,7	10,4	5,3	10,1
Comp. Example 1b	19,8	18,4	7,6	16,6
Comp. Example 2	88,6	63,3	---	---
Comp. Example 3	110,9	86	---	---

In Table 5 the selectivity of CO₂ over Sevoflurane as obtained from the mixed gas experiments is listed together with the pure CO₂ permeance for hollow fiber membranes of Examples 1 to 3 and Comparative Examples 1 to 3. Sufficiently high selectivities CO₂ / Sevoflurane resulting in a good retention of anesthetic gases by the membranes with at the same time sufficiently high permeances for CO₂ are obtained for the membranes of Examples 1 to 3. Figure 4 shows a diagram of the selectivity CO₂ / Sevoflurane in dependency of the pure CO₂ permeance.

Table 5:

	Solvent system/ polymer ratio	Pure CO₂ Permeance (mol / m² / bar / h)	Selectivity α_{ij} CO₂/Sevoflurane
Example 1	1.18	23.1	1130
Example 2	1.20	32.3	550
Example 3	1.22	31.8	250
Comp. Example 1a	1.17	16.7	1450
Comp. Example 2	1.35	88.6	86
Comp. Example 3	1.44	110.9	93

Figure 5 plots the CO₂/Sevoflurane selectivity as a function of the CO₂ permeance
 5 for the Examples and Comparative Examples listed in Table 5.

This patent application filing claims priority to European patent application number
 EP 16166434.7 filed on April 21, 2016, the specification having numbered pages
 1-45 and Figures 1-10 on drawing sheets 1-6, the disclosure of which is herein
 10 incorporated by reference in its entirety.

Claims:

1. Integrally asymmetrical hydrophobic hollow fiber membrane for retention of anesthetic agents, which membrane is composed primarily of a poly(4-methyl-
5 1-pentene) and has an inner surface facing towards its lumen, an outer surface facing outwards, a support layer with a sponge-like, open-pored, microporous structure between inner surface and outer surface and adjacent to this support layer on the outer surface a separation layer with denser structure, wherein the support layer is free of macrovoids and the pores in the support layer are
10 on average essentially isotropic, characterized in that
- the separation layer has a thickness in the range between 1.0 and 3.5 μm and,
 - that the membrane has a permeance for CO_2 of 20-60 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$, a gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ of at least 5 and a selectivity CO_2 / anesthetic agents of at least 150
 - and that the membrane has a porosity in the range of greater than 35% to less than 50% by volume.
- 20 2. Membrane according to Claim 1, characterized in that the membrane structure changes abruptly in the transition from the separation to the support layer.
3. Membrane according to Claim 1 or 2, characterized in that the separation layer has a thickness between 1.0 μm and 2.0 μm .
- 25 4. Membrane according to one or more of Claims 1 to 3, characterized in that the membrane has a permeance for CO_2 of 25-40 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$.
5. Membrane according to one or more of Claims 1 to 4, characterized in that the
30 membrane has a permeance for CO_2 of 25-40 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$ and an O_2 permeance of at least 10 $\text{mol}/(\text{h}\cdot\text{m}^2\cdot\text{bar})$.

6. Membrane according to one or more of Claims 1 to 5, characterized in that it has a selectivity CO_2 / anesthetic agents of at least 220.
- 5 7. Membrane according to one or more of Claims 1 to 5, characterized in that it has a selectivity CO_2 / anesthetic agents of at least 400.
8. Membrane according to one or more of Claims 1 to 7, characterized in that it has a gas separation factor $\alpha(\text{CO}_2/\text{N}_2)$ of at least 8 .
- 10 9. Process for producing an integrally asymmetrical hydrophobic hollow fiber membrane according to one or more of claims 1 to 8, the process comprising at least the steps of:
- a) preparing a homogeneous solution of a polymer component consisting of
15 a poly(4-methyl-1-pentene) in a solvent system containing a component A and a component B that are liquid and miscible with each other at the dissolving temperature, whereby the employed mixture of the polymer component and components A and B has a critical demixing temperature and a solidification temperature and has a miscibility gap in the liquid state
20 of aggregation below the critical demixing temperature, whereby a strong solvent for the polymer component is selected for component A, for which the demixing temperature of a solution of 25% by weight of the polymer component in this solvent is at least 10% below the melting point of the pure polymer component, wherein demixing temperature and melting point
25 are measured in °C, and component B raises the demixing temperature of a solution consisting of the polymer component and component A, wherein component B is a weak non-solvent for the polymer component, which does not dissolve the polymer component to form a homogeneous solution when heated to the boiling point of component B and for which the
30 demixing temperature of a system consisting of 25% by weight of the polymer component, 10% by weight of the weak non-solvent, and 65% by

weight of component A, used as the solvent, is at most 10% above the demixing temperature of a system consisting of 25% by weight of the polymer component and 75% by weight of component A, wherein the temperatures are measured in °C,

- 5 b) rendering the solution to form a hollow fiber, with outer and inner surfaces, in a die having an exit surface and a die temperature above the critical demixing temperature,
- c) cooling of the hollow fiber using a liquid cooling medium having an entrance surface, which cooling medium does not dissolve the polymer
10 component or react chemically with it at temperatures up to the die temperature and is tempered to a cooling temperature below the solidification temperature, wherein the cooling medium is a homogeneous, single-phase liquid at the cooling temperature and the cooling is done at such a rate that a thermodynamic non-equilibrium liquid-liquid phase
15 separation into a high-polymer-content phase and a low-polymer content phase takes place and solidification of the high-polymer-content phase subsequently occurs when the temperature falls below the solidification temperature,
- d) possibly removing components A and B from the hollow fiber,
20 characterized in that the concentration of the polymer component in the homogeneous solution is in the range from 42.5 to 45.8% by weight and the concentration of the solvent system in the range from 57.5 to 54.2% by weight and that the hollow fiber leaving the die runs through a gap between the exit surface of the die and the surface of the cooling medium before entering the
25 cooling medium, wherein the gap has a length in the range of 5-30 mm.

10. Process according to Claim 9, characterized in that the cooling medium is a liquid that is a strong non-solvent for the polymer component, for which the demixing temperature of a system consisting of 25% by weight of the polymer
30 component, 10% by weight of the strong non-solvent, and 65% by weight of component A, used as a solvent, is at least 10% higher than the demixing

temperature of a system consisting of 25% by weight of the polymer component and 75% by weight of component A.

- 5 11. Process according to Claim 9 or 10, characterized in that the concentration of the polymer component in the homogeneous solution is in the range of 43-45.5% by weight and the concentration of the solvent system in the range of 57-54.5% by weight.
- 10 12. Process according to one or more of Claims 9 to 11, characterized in that dioctyl adipate, isopropyl myristate, diphenyl ether, dibenzyl ether, or a mixture thereof is used as component A.
- 15 13. Process according to one or more of Claims 9 to 12, characterized in that glycerin triacetate, diethyl phthalate, castor oil, N,N-bis(2-hydroxyethyl)tallow amine, soybean oil, or a mixture thereof is used as component B.
14. Process according to Claim 12, characterized in that dioctyl adipate is used as component A.
- 20 15. Use of a membrane according to one or more of Claims 1 to 8 in an anesthetic circuit.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/028525

A. CLASSIFICATION OF SUBJECT MATTER
 INV. B01D69/08 B01D53/22 B01D71/26
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 B01D
 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 497 752 B1 (KESSLER ERICH [DE] ET AL) 24 December 2002 (2002-12-24) cited in the application	1-14
Y	claim 1 claim 15 claim 11	15
Y	----- WO 2014/094139 A1 (DMF MEDICAL INC [CA]) 26 June 2014 (2014-06-26) cited in the application the whole document -----	15
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search 18 July 2017	Date of mailing of the international search report 27/07/2017
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Hoyer, Michael
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/028525

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHRISTOPH WIESENACK ET AL: "In Vivo Uptake and Elimination of Isoflurane by Different Membrane Oxygenators during Cardiopulmonary Bypass", ANESTHESIOLOGY., vol. 97, no. 1, 1 July 2002 (2002-07-01), pages 133-138, XP055312250, PHILADELPHIA, PA, US ISSN: 0003-3022, DOI: 10.1097/00000542-200207000-00019 the whole document	15
A	----- WO 03/061812 A2 (MEMBRANA GMBH [DE]; KESSLER ERICH [DE]; BATZILLA THOMAS [DE]; WECHS FR) 31 July 2003 (2003-07-31) the whole document	1-15
A	----- CN 104 707 490 A (HANGZHOU FAIR FILTRATION TECHNOLOGY CO LTD) 17 June 2015 (2015-06-17) the whole document	1-15
A	----- KR 100 654 083 B1 (BATZILLA) 7 December 2006 (2006-12-07) the whole document	1-15
A	----- US 6 375 876 B1 (KESSLER ERICH [DE] ET AL) 23 April 2002 (2002-04-23) the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2017/028525

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6497752	B1	24-12-2002	AT 250971 T 15-10-2003
			AU 748844 B2 13-06-2002
			BR 0007614 A 30-10-2001
			CA 2359050 A1 27-07-2000
			CN 1336848 A 20-02-2002
			DK 1144096 T3 09-02-2004
			EP 1144096 A1 17-10-2001
			ES 2204513 T3 01-05-2004
			JP 4996011 B2 08-08-2012
			JP 2002535115 A 22-10-2002
			US 6497752 B1 24-12-2002
WO 0043114 A1 27-07-2000			

WO 2014094139	A1	26-06-2014	CA 2895224 A1 26-06-2014
			EP 2934645 A1 28-10-2015
			JP 2016500306 A 12-01-2016
			US 2014174438 A1 26-06-2014
			WO 2014094139 A1 26-06-2014

WO 03061812	A2	31-07-2003	AT 337080 T 15-09-2006
			BR 0306850 A 03-11-2004
			CA 2477190 A1 31-07-2003
			CN 1622850 A 01-06-2005
			EP 1469935 A2 27-10-2004
			JP 4217627 B2 04-02-2009
			JP 2005515061 A 26-05-2005
			US 2005145107 A1 07-07-2005
			WO 03061812 A2 31-07-2003

CN 104707490	A	17-06-2015	NONE

KR 100654083	B1	07-12-2006	NONE

US 6375876	B1	23-04-2002	AU 747646 B2 16-05-2002
			CN 1336849 A 20-02-2002
			DK 1140331 T3 07-04-2003
			EP 1140331 A1 10-10-2001
			JP 4095773 B2 04-06-2008
			JP 2002535114 A 22-10-2002
			US 6375876 B1 23-04-2002
			WO 0043113 A1 27-07-2000
